Progressive foot swelling in BUF rats. A new animal model for screening of anti-inflammatory and anti-rheumatic drugs.
Buffalo rats of a low adjuvant-arthritis responder strain demonstrate a continually increasing swelling in the hind foot inoculated with mycobacterial adjuvant, characterized by extensive panostitis, new bone formation and long-delayed bony calcification. A rapid regression of foot swelling was produced by a three-day course of therapy with indomethacin (1 mg/kg) or with dexamethasone (0.1 mg/kg), but a definite rebound was followed soon after termination of the therapy. This recurrent episode occurred repeatedly in the second and third therapeutic trials with the anti-inflammatory drugs in the same animals. The 5 days treatment with either levamisole (5 mg/kg) or cyclophosphamide (5 mg/kg) prevented further increase in the swelling for a long time period after withdrawal of the drug, and enhanced bone mineralization.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy*; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005260:Female; D005534:Foot Diseases / Q000188:drug therapy; D007213:Indomethacin / Q000627:therapeutic use; D007978:Levamisole / Q000627:therapeutic use; D008297:Male; D051381:Rats; D011915:Rats, Inbred BUF
D000893:Anti-Inflammatory Agents; D007978:Levamisole; D003907:Dexamethasone; D003520:Cyclophosphamide; D007213:Indomethacin